Nanotherapeutics in Cancer Vaccination and Challenges
portes grátis
Nanotherapeutics in Cancer Vaccination and Challenges
H Almalki, Waleed; Beg, Sarwar; Rahman, Mahfoozur; Choudhry, Hani; Alhakamy, Nabil A.
Elsevier Science Publishing Co Inc
03/2022
494
Mole
Inglês
9780128236864
15 a 20 dias
770
Descrição não disponível.
1. Cancer vaccines: Past, present and future
2. Inorganic Nanoparticulate Carriers in management of Cancer: Theranostic and Toxicity Apprehension
3. Recent developments in cancer vaccines: Where are we?
4. Application of Nanotechnology assisted devices in cancer treatment
5. Protein Based Nanocarriers as a Potent Drug Delivery Vehicle for Cancer Therapy
6. Nanoparticle-based manipulation of antigen-presenting cells for cancer immunotherapy
7. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies
8. Peptide based anticancer targeted therapeutics: State of the Art
9. Polyplexes-based delivery systems for cancer vaccine delivery
10. Lipopolyplexes-based delivery system for cancer vaccine delivery
11. Inorganic nanoparticulate carriers in cancer vaccination
12. Functional nanomaterials and nanocomposites in cancer vaccines
13. DNA vaccines for cancer treatment: Challenges and promises
14. mRNA-based nanovaccines as newer treatment modalities in cancer
15. Cancer immunotherapy: Moving forward with peptide T cell vaccines
16. Product development and scale-up challenges in cancer vaccine development
17. Regulatory landscape in the approval of cancer vaccines
18. Cross-Presentation-based Nanovaccine for Cancer Immunotherapy
19. Immunotherapy based cancer Vaccines: State of the art
20. Therapeutics peptides in Anticancer therapy
21. Inorganic Nanoconjugates For Cancer Theragnosis
2. Inorganic Nanoparticulate Carriers in management of Cancer: Theranostic and Toxicity Apprehension
3. Recent developments in cancer vaccines: Where are we?
4. Application of Nanotechnology assisted devices in cancer treatment
5. Protein Based Nanocarriers as a Potent Drug Delivery Vehicle for Cancer Therapy
6. Nanoparticle-based manipulation of antigen-presenting cells for cancer immunotherapy
7. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies
8. Peptide based anticancer targeted therapeutics: State of the Art
9. Polyplexes-based delivery systems for cancer vaccine delivery
10. Lipopolyplexes-based delivery system for cancer vaccine delivery
11. Inorganic nanoparticulate carriers in cancer vaccination
12. Functional nanomaterials and nanocomposites in cancer vaccines
13. DNA vaccines for cancer treatment: Challenges and promises
14. mRNA-based nanovaccines as newer treatment modalities in cancer
15. Cancer immunotherapy: Moving forward with peptide T cell vaccines
16. Product development and scale-up challenges in cancer vaccine development
17. Regulatory landscape in the approval of cancer vaccines
18. Cross-Presentation-based Nanovaccine for Cancer Immunotherapy
19. Immunotherapy based cancer Vaccines: State of the art
20. Therapeutics peptides in Anticancer therapy
21. Inorganic Nanoconjugates For Cancer Theragnosis
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Active immunity; Allogenic tumor cell vaccine; Anticancer therapeutics; Antigen discovery; Autologoustumor cell vaccine; Bloodstream; Bone marrow; Breast cancer; Cancer chemotherapy; Cancer immunotherapy; Cancer vaccination; Cancer vaccine; Cancer; Cancerimmunotherapy; Cancers; Cancertherapy; Carbon nanotube; Cell-targeting peptides; Cervarix; Chemotherapy; Costimulation; Cross-presentation; C-type lectin receptor; DC-SIGN; Dendritic cells; Diagnostic agents; DNA vaccines; DNA; EPR effect; Functional nanomaterials; Genetic vaccine; Glycan; Gold nanoparticles; Goldnanoparticle; Immune modulation; Immune system; Immunology; Immunotherapy; Inorganic nanoparticles; Iron oxide nanoparticles; Lectin; Leukemia; Lipopolyplex; Liposomal nanocarrier; Liposomes; Lung cancer; Lymphatic system; Medical devices; mRNA nanovaccine; Nanodevices; Nanomaterial; Nanomedicine; Nanomedicines; Nanoparticle systems; Nanoparticles; Nanotechnology; Neoantigen; Nucleic acids; Peptide T-cell cancer vaccine; Peptide-based medicinal conjugates; Peptide-based nanovaccines; Peptides; pH-sensitive liposomes; Plant lectin; Polymeric nanoparticles; Polyplexes; Private antigen; Product development; Prophylactic vaccine; Protein/peptide-based vaccine; Protein-based nanocarriers; Public antigen; Quantum dot; Regulations; Route of administration; Scale-up; Silica nanoparticles; Targeted delivery; Targeted therapy; T-cell receptor; Theranostics nanoparticles; TIL; T-lymphocytes; Tolerance; Toxicity; Transcutaneous use; Tumor drug targeting; Tumor homing peptides; Tumor; Tumor-associated antigens; Tumour targeting; Vaccination; Vaccine and immunotherapy; Vaccine; Vaccines
1. Cancer vaccines: Past, present and future
2. Inorganic Nanoparticulate Carriers in management of Cancer: Theranostic and Toxicity Apprehension
3. Recent developments in cancer vaccines: Where are we?
4. Application of Nanotechnology assisted devices in cancer treatment
5. Protein Based Nanocarriers as a Potent Drug Delivery Vehicle for Cancer Therapy
6. Nanoparticle-based manipulation of antigen-presenting cells for cancer immunotherapy
7. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies
8. Peptide based anticancer targeted therapeutics: State of the Art
9. Polyplexes-based delivery systems for cancer vaccine delivery
10. Lipopolyplexes-based delivery system for cancer vaccine delivery
11. Inorganic nanoparticulate carriers in cancer vaccination
12. Functional nanomaterials and nanocomposites in cancer vaccines
13. DNA vaccines for cancer treatment: Challenges and promises
14. mRNA-based nanovaccines as newer treatment modalities in cancer
15. Cancer immunotherapy: Moving forward with peptide T cell vaccines
16. Product development and scale-up challenges in cancer vaccine development
17. Regulatory landscape in the approval of cancer vaccines
18. Cross-Presentation-based Nanovaccine for Cancer Immunotherapy
19. Immunotherapy based cancer Vaccines: State of the art
20. Therapeutics peptides in Anticancer therapy
21. Inorganic Nanoconjugates For Cancer Theragnosis
2. Inorganic Nanoparticulate Carriers in management of Cancer: Theranostic and Toxicity Apprehension
3. Recent developments in cancer vaccines: Where are we?
4. Application of Nanotechnology assisted devices in cancer treatment
5. Protein Based Nanocarriers as a Potent Drug Delivery Vehicle for Cancer Therapy
6. Nanoparticle-based manipulation of antigen-presenting cells for cancer immunotherapy
7. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies
8. Peptide based anticancer targeted therapeutics: State of the Art
9. Polyplexes-based delivery systems for cancer vaccine delivery
10. Lipopolyplexes-based delivery system for cancer vaccine delivery
11. Inorganic nanoparticulate carriers in cancer vaccination
12. Functional nanomaterials and nanocomposites in cancer vaccines
13. DNA vaccines for cancer treatment: Challenges and promises
14. mRNA-based nanovaccines as newer treatment modalities in cancer
15. Cancer immunotherapy: Moving forward with peptide T cell vaccines
16. Product development and scale-up challenges in cancer vaccine development
17. Regulatory landscape in the approval of cancer vaccines
18. Cross-Presentation-based Nanovaccine for Cancer Immunotherapy
19. Immunotherapy based cancer Vaccines: State of the art
20. Therapeutics peptides in Anticancer therapy
21. Inorganic Nanoconjugates For Cancer Theragnosis
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Active immunity; Allogenic tumor cell vaccine; Anticancer therapeutics; Antigen discovery; Autologoustumor cell vaccine; Bloodstream; Bone marrow; Breast cancer; Cancer chemotherapy; Cancer immunotherapy; Cancer vaccination; Cancer vaccine; Cancer; Cancerimmunotherapy; Cancers; Cancertherapy; Carbon nanotube; Cell-targeting peptides; Cervarix; Chemotherapy; Costimulation; Cross-presentation; C-type lectin receptor; DC-SIGN; Dendritic cells; Diagnostic agents; DNA vaccines; DNA; EPR effect; Functional nanomaterials; Genetic vaccine; Glycan; Gold nanoparticles; Goldnanoparticle; Immune modulation; Immune system; Immunology; Immunotherapy; Inorganic nanoparticles; Iron oxide nanoparticles; Lectin; Leukemia; Lipopolyplex; Liposomal nanocarrier; Liposomes; Lung cancer; Lymphatic system; Medical devices; mRNA nanovaccine; Nanodevices; Nanomaterial; Nanomedicine; Nanomedicines; Nanoparticle systems; Nanoparticles; Nanotechnology; Neoantigen; Nucleic acids; Peptide T-cell cancer vaccine; Peptide-based medicinal conjugates; Peptide-based nanovaccines; Peptides; pH-sensitive liposomes; Plant lectin; Polymeric nanoparticles; Polyplexes; Private antigen; Product development; Prophylactic vaccine; Protein/peptide-based vaccine; Protein-based nanocarriers; Public antigen; Quantum dot; Regulations; Route of administration; Scale-up; Silica nanoparticles; Targeted delivery; Targeted therapy; T-cell receptor; Theranostics nanoparticles; TIL; T-lymphocytes; Tolerance; Toxicity; Transcutaneous use; Tumor drug targeting; Tumor homing peptides; Tumor; Tumor-associated antigens; Tumour targeting; Vaccination; Vaccine and immunotherapy; Vaccine; Vaccines
